Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Ritonavir (Norvir)
 
Journal Citations: Clinical
Pharmacology

Pharmacokinetics
 Resistance
 Cross Resistance
 Viral Dynamics
 Drug Interactions 
 Adverse Events
 Efficacy



 
Ritonavir Main Page Drugs Main Page   Home Page    
Last Update:  December 22, 2005
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Pharmacokinetics
 
 
Effects of the HIV-Protease Inhibitor Ritonavir on Basal and Catecholamine-
Stimulated Lipolysis
Adler-Wailes DC, Liu H, et al 
J Clin Endocrinol Metab. 2005 Mar
Abstract 
 
Ritonavir Decreases the Nonrenal Clearance of Digoxin in Healthy Volunteers
with Known MDR1 Genotypes.
 Penzak SR, Shen JM, Alfaro RM, et al
Ther Drug Monit. 2004 Jun;26(3):322-330.
Abstract 
 
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir
is not sufficient to inhibit differentiation.
Vernochet C, Azoulay S, Duval D, et al
AIDS. 2003 Oct 17;17(15):2177-80.
Abstract 
 
Effects of Ritonavir on Indinavir Pharmacokinetics in Cerebrospinal Fluid and Plasma.
 Haas DW, Johnson B, Nicotera J, et al
Antimicrob Agents Chemother. 2003 Jul;47(7):2131-2137.
Abstract 

Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-
Infected Patients.
 Shelton MJ, Hewitt RG, Adams J, et al.
Antimicrob Agents Chemother 2003 May;47(5):1694-1699
 Abstract 

Effect of short-term administration of garlic supplements on single-dose ritonavir
pharmacokinetics in healthy volunteers.
Gallicano K, Foster B, Choudhri S. et al.
Br J Clin Pharmacol 2003 Feb;55(2):199-202
 Abstract 

Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir,
Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration.
Lu JF, Blaschke TF, Flexner C, et al
 Abstract  

Ritonavir inhibition of calcium-activated neutral proteases.
 Wan W, DePetrillo PB.
Biochem Pharmacol 2002 Apr 15;63(8):1481-1484
Abstract  

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and
saquinavir (soft gelatin capsules) administration.
Buss N, Snell P, Bock J, Hsu A, Jorga K.
Br J Clin Pharmacol 2001 Sep;52(3):255-64
 Abstract 

  
Resistance
 
  The cumulative occurrence of resistance mutations in the HIV-1 protease gene
is associated with failure of salvage therapy with ritonavir and saquinavir in
protease inhibitor-experienced patients.
Karmochkine M, Si Mohamed A, Piketty C, et al.
Antiviral Res 2000 Sep;47(3):179-88
Abstract
Cross Resistance
 

FULL-TEXT ARTICLE
Human immunodeficiency virus type 1 protease cleavage site mutations |
associated with protease inhibitor cross-resistance selected by indinavir,